Katsiaryna Bykov, Pharm.D., Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Interactions | 11 | 2021 | 1460 | 2.480 |
Why?
|
| Cross-Over Studies | 4 | 2020 | 2029 | 1.540 |
Why?
|
| Warfarin | 6 | 2023 | 1496 | 1.200 |
Why?
|
| Venous Thromboembolism | 3 | 2023 | 1671 | 1.060 |
Why?
|
| Analgesics, Opioid | 8 | 2024 | 3674 | 0.940 |
Why?
|
| Anticoagulants | 7 | 2023 | 4599 | 0.810 |
Why?
|
| Ticlopidine | 3 | 2017 | 899 | 0.810 |
Why?
|
| Oxycodone | 2 | 2022 | 153 | 0.770 |
Why?
|
| Rhabdomyolysis | 2 | 2019 | 150 | 0.770 |
Why?
|
| Pharmacoepidemiology | 2 | 2023 | 323 | 0.760 |
Why?
|
| Drug Evaluation | 2 | 2020 | 647 | 0.720 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2018 | 30 | 0.660 |
Why?
|
| Metoprolol | 1 | 2018 | 93 | 0.640 |
Why?
|
| Pain, Postoperative | 5 | 2021 | 1643 | 0.610 |
Why?
|
| Hemophilia B | 1 | 2017 | 81 | 0.600 |
Why?
|
| Pyridones | 1 | 2022 | 712 | 0.590 |
Why?
|
| Factor VIIa | 1 | 2017 | 101 | 0.590 |
Why?
|
| Urinary Tract Infections | 2 | 2022 | 788 | 0.590 |
Why?
|
| Drug Utilization | 3 | 2020 | 1183 | 0.580 |
Why?
|
| Antithrombins | 2 | 2019 | 304 | 0.580 |
Why?
|
| Cardiovascular Agents | 4 | 2015 | 850 | 0.570 |
Why?
|
| Data Mining | 1 | 2021 | 537 | 0.550 |
Why?
|
| Epidemiologic Research Design | 1 | 2019 | 367 | 0.540 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 355 | 0.520 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 3255 | 0.500 |
Why?
|
| Hemophilia A | 1 | 2017 | 351 | 0.490 |
Why?
|
| Medication Adherence | 5 | 2018 | 2063 | 0.470 |
Why?
|
| Research Design | 4 | 2021 | 5987 | 0.450 |
Why?
|
| Myocardial Infarction | 6 | 2018 | 11727 | 0.440 |
Why?
|
| Hemorrhage | 4 | 2023 | 3461 | 0.430 |
Why?
|
| Cohort Studies | 18 | 2023 | 40561 | 0.420 |
Why?
|
| Electronic Health Records | 2 | 2019 | 4468 | 0.410 |
Why?
|
| Suicide | 1 | 2022 | 1477 | 0.410 |
Why?
|
| Pyrazoles | 1 | 2022 | 1972 | 0.400 |
Why?
|
| Thromboembolism | 1 | 2017 | 986 | 0.390 |
Why?
|
| Hypoglycemic Agents | 3 | 2023 | 2872 | 0.370 |
Why?
|
| Clarithromycin | 2 | 2020 | 86 | 0.350 |
Why?
|
| Azithromycin | 2 | 2022 | 196 | 0.350 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 310 | 0.350 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 1130 | 0.340 |
Why?
|
| Inpatients | 1 | 2021 | 2518 | 0.340 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 115 | 0.330 |
Why?
|
| Databases, Factual | 11 | 2021 | 7729 | 0.330 |
Why?
|
| Insurance, Health | 2 | 2020 | 2494 | 0.320 |
Why?
|
| Medicare | 4 | 2023 | 6566 | 0.300 |
Why?
|
| Cholesterol | 1 | 2016 | 2917 | 0.300 |
Why?
|
| Prescription Drugs | 3 | 2024 | 595 | 0.290 |
Why?
|
| Case-Control Studies | 4 | 2021 | 21746 | 0.290 |
Why?
|
| Treatment Failure | 1 | 2012 | 2618 | 0.290 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2016 | 3068 | 0.280 |
Why?
|
| Data Collection | 1 | 2015 | 3341 | 0.280 |
Why?
|
| Healthcare Disparities | 3 | 2016 | 3158 | 0.270 |
Why?
|
| Cerebral Hemorrhage | 2 | 2016 | 2647 | 0.270 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 2065 | 0.270 |
Why?
|
| Propensity Score | 8 | 2020 | 1781 | 0.270 |
Why?
|
| United States | 17 | 2023 | 69872 | 0.260 |
Why?
|
| Humans | 52 | 2024 | 744343 | 0.250 |
Why?
|
| Patient Readmission | 1 | 2018 | 3114 | 0.240 |
Why?
|
| Baclofen | 2 | 2022 | 129 | 0.240 |
Why?
|
| Middle Aged | 24 | 2023 | 213383 | 0.240 |
Why?
|
| Parkinson Disease | 2 | 2016 | 2775 | 0.220 |
Why?
|
| Norfloxacin | 1 | 2022 | 25 | 0.220 |
Why?
|
| Carisoprodol | 1 | 2022 | 5 | 0.220 |
Why?
|
| Methocarbamol | 1 | 2022 | 7 | 0.220 |
Why?
|
| Aged | 23 | 2023 | 163280 | 0.220 |
Why?
|
| Drug Substitution | 2 | 2016 | 281 | 0.210 |
Why?
|
| Hyperkalemia | 1 | 2023 | 218 | 0.200 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5319 | 0.200 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2015 | 430 | 0.200 |
Why?
|
| Paroxetine | 1 | 2022 | 182 | 0.190 |
Why?
|
| Methods | 1 | 2021 | 1129 | 0.190 |
Why?
|
| Hospitalization | 6 | 2022 | 10262 | 0.190 |
Why?
|
| Lorazepam | 1 | 2021 | 145 | 0.190 |
Why?
|
| Neuromuscular Agents | 1 | 2022 | 134 | 0.190 |
Why?
|
| Ciprofloxacin | 1 | 2022 | 315 | 0.190 |
Why?
|
| Drugs, Generic | 2 | 2016 | 421 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 5751 | 0.190 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2015 | 1683 | 0.190 |
Why?
|
| Epidemiology | 1 | 2023 | 287 | 0.180 |
Why?
|
| Coronary Artery Bypass | 3 | 2015 | 2289 | 0.180 |
Why?
|
| Retrospective Studies | 10 | 2023 | 77449 | 0.180 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 6489 | 0.180 |
Why?
|
| Female | 29 | 2023 | 380194 | 0.180 |
Why?
|
| Stroke | 3 | 2017 | 9981 | 0.170 |
Why?
|
| Male | 26 | 2023 | 350118 | 0.170 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2023 | 293 | 0.170 |
Why?
|
| Control Groups | 1 | 2019 | 105 | 0.170 |
Why?
|
| Time Factors | 5 | 2022 | 40075 | 0.170 |
Why?
|
| Adult | 17 | 2023 | 214055 | 0.170 |
Why?
|
| Insurance Claim Review | 2 | 2021 | 720 | 0.160 |
Why?
|
| Postoperative Period | 2 | 2021 | 1842 | 0.160 |
Why?
|
| Simvastatin | 1 | 2020 | 360 | 0.160 |
Why?
|
| Fluoxetine | 1 | 2022 | 749 | 0.150 |
Why?
|
| Hospitals | 2 | 2022 | 3952 | 0.150 |
Why?
|
| Computer Simulation | 3 | 2020 | 6196 | 0.150 |
Why?
|
| Health Services | 1 | 2022 | 758 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 7181 | 0.140 |
Why?
|
| Osteoarthritis | 1 | 2024 | 1036 | 0.140 |
Why?
|
| Aortic Aneurysm | 1 | 2020 | 643 | 0.130 |
Why?
|
| Names | 1 | 2015 | 52 | 0.130 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2015 | 126 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2015 | 2282 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 968 | 0.130 |
Why?
|
| Ketorolac | 1 | 2015 | 79 | 0.130 |
Why?
|
| Community Pharmacy Services | 1 | 2014 | 46 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2022 | 3913 | 0.120 |
Why?
|
| Comparative Effectiveness Research | 2 | 2023 | 681 | 0.120 |
Why?
|
| Risk Factors | 9 | 2021 | 72290 | 0.110 |
Why?
|
| Prevalence | 2 | 2021 | 15226 | 0.110 |
Why?
|
| Information Systems | 1 | 2015 | 410 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 1248 | 0.110 |
Why?
|
| Models, Theoretical | 2 | 2015 | 3589 | 0.110 |
Why?
|
| Thrombophilia | 1 | 2015 | 305 | 0.110 |
Why?
|
| Anti-Ulcer Agents | 1 | 2013 | 119 | 0.110 |
Why?
|
| Osteoarthritis, Hip | 1 | 2017 | 412 | 0.110 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 841 | 0.110 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 165 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 476 | 0.110 |
Why?
|
| Algorithms | 1 | 2012 | 13881 | 0.100 |
Why?
|
| Recurrence | 2 | 2022 | 8340 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12354 | 0.100 |
Why?
|
| Cephalosporins | 1 | 2013 | 204 | 0.100 |
Why?
|
| Logistic Models | 4 | 2020 | 13408 | 0.100 |
Why?
|
| Fractures, Bone | 1 | 2024 | 1947 | 0.100 |
Why?
|
| Tamoxifen | 1 | 2016 | 981 | 0.100 |
Why?
|
| Comorbidity | 3 | 2022 | 10388 | 0.100 |
Why?
|
| Reminder Systems | 1 | 2014 | 371 | 0.100 |
Why?
|
| Financing, Personal | 1 | 2014 | 308 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 789 | 0.100 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 264 | 0.100 |
Why?
|
| Atrial Fibrillation | 2 | 2023 | 5034 | 0.100 |
Why?
|
| Prescriptions | 2 | 2024 | 387 | 0.090 |
Why?
|
| Neoplasms | 1 | 2019 | 21683 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 1917 | 0.090 |
Why?
|
| Benzodiazepines | 3 | 2022 | 1101 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2019 | 63114 | 0.090 |
Why?
|
| Vancomycin | 1 | 2013 | 501 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 2208 | 0.090 |
Why?
|
| Dementia | 1 | 2023 | 2518 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 3610 | 0.080 |
Why?
|
| Young Adult | 7 | 2020 | 56430 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2013 | 526 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 1 | 2015 | 773 | 0.080 |
Why?
|
| Sepsis | 1 | 2022 | 2593 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 1524 | 0.080 |
Why?
|
| Substance-Related Disorders | 2 | 2022 | 4258 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 6622 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 639 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2015 | 2309 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2020 | 9849 | 0.080 |
Why?
|
| Cesarean Section | 1 | 2016 | 1365 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 57776 | 0.070 |
Why?
|
| Pneumonia | 2 | 2020 | 2133 | 0.070 |
Why?
|
| Pain | 1 | 2022 | 4986 | 0.070 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 1222 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 1637 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 1462 | 0.070 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 7659 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2015 | 2050 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 1458 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2018 | 3313 | 0.070 |
Why?
|
| Risk | 1 | 2017 | 9687 | 0.060 |
Why?
|
| Incidence | 3 | 2020 | 20947 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1797 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 1956 | 0.060 |
Why?
|
| Self Report | 1 | 2015 | 3558 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5102 | 0.060 |
Why?
|
| Seizures | 1 | 2016 | 2859 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1416 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1540 | 0.060 |
Why?
|
| Orphenadrine | 1 | 2022 | 4 | 0.060 |
Why?
|
| Chlorzoxazone | 1 | 2022 | 7 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 4933 | 0.050 |
Why?
|
| Hydrocodone | 1 | 2022 | 47 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2022 | 110 | 0.050 |
Why?
|
| Depression | 1 | 2022 | 7766 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7785 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 11725 | 0.050 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 86 | 0.050 |
Why?
|
| Epilepsy | 1 | 2016 | 3310 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2023 | 468 | 0.050 |
Why?
|
| Smoking | 2 | 2016 | 8987 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2017 | 41006 | 0.050 |
Why?
|
| Risk Assessment | 6 | 2021 | 23338 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2017 | 25625 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2021 | 449 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39050 | 0.040 |
Why?
|
| Adolescent | 5 | 2017 | 85781 | 0.040 |
Why?
|
| Infant | 2 | 2017 | 35136 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 15165 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2022 | 562 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 5137 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2016 | 6600 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2016 | 165 | 0.030 |
Why?
|
| Etodolac | 1 | 2015 | 20 | 0.030 |
Why?
|
| Child | 3 | 2017 | 77709 | 0.030 |
Why?
|
| Insurance Coverage | 2 | 2015 | 1901 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2021 | 1162 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1584 | 0.030 |
Why?
|
| New Jersey | 1 | 2013 | 290 | 0.030 |
Why?
|
| Lactones | 1 | 2015 | 329 | 0.030 |
Why?
|
| Sulfones | 1 | 2015 | 437 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2015 | 294 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1071 | 0.030 |
Why?
|
| Health Services Misuse | 1 | 2014 | 243 | 0.030 |
Why?
|
| Embolism | 1 | 2015 | 408 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2013 | 613 | 0.030 |
Why?
|
| Peptic Ulcer | 1 | 2013 | 223 | 0.030 |
Why?
|
| Back Pain | 1 | 2016 | 545 | 0.030 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2014 | 336 | 0.020 |
Why?
|
| Telephone | 1 | 2014 | 617 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 451 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15295 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12245 | 0.020 |
Why?
|
| Age Distribution | 1 | 2016 | 2902 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 20822 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1240 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2015 | 1486 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 2971 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 1518 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2013 | 956 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2016 | 1916 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2016 | 6459 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1403 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 2838 | 0.010 |
Why?
|
| Migraine Disorders | 1 | 2016 | 1620 | 0.010 |
Why?
|
| Length of Stay | 1 | 2017 | 6309 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3265 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 10943 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2015 | 53288 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 9959 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 29144 | 0.010 |
Why?
|